Rate of Incomplete Revascularization Following Coronary Artery Bypass Grafting at a Single Institution Between 2007 and 2017

Soukup, Chase R; Schmidt, Christian; Chan-Tram, Carmen; Garberich, Ross; Sun, Benjamin; Traverse, Jay H.

doi:10.1016/j.amjcard.2020.12.064

Cited by 2 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All study personnel are blinded to the treatment groups. A manuscript from our laboratory outlines the specific details of this model using cardiac magnetic resonance (CMR) imaging to define the extent of scar area in the left ventricle 1-month after MI [24] .…”

Section: Outline Of Study Of Tissue Engineered Patch In Yucatan Mini ...mentioning

confidence: 99%

“…We obtained CMR imaging at baseline, 1-month, 2-months, 4-months and 7-months after MI to obtain measurements of LV volume, LV mass, and scar size. We use the CMR image obtained at 1-month after MI to define the scar's location to help guide the surgeon on where to place the TE patch [Figure 7] [24] . We found this is important because the infarct area routinely extends beyond the visual assessment of the scar area seen in the operating room.…”

Section: Cardiac Magnetic Resonance (Cmr) Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial

Goldman¹,

Traverse²,

Zile³

et al. 2022

Vessel Plus

Self Cite

View full text Add to dashboard Cite

This perspective focuses on the development of tissue engineered (TE) cell-based therapies to treat left ventricular (LV) dysfunction and chronic heart failure (CHF). The development of induced pluripotent stem cells enabled investigators to seed or co-culture human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) alone and in combination with other cells onto bioengineered scaffolds applied to the epicardial surface of the damaged left ventricle. Using our work as an example, we show how a xenograft implant of a bioengineered scaffold embedded with human neonatal fibroblasts and seeded with hiPSC-CMs partially reversed maladaptive LV remodeling and improved LV systolic/diastolic function in an immune-competent rat model of CHF. The fibroblasts lay down an extracellular matrix and secrete growth factors that increase myocardial blood flow. This approach provides an improved cell payload that covers a larger area of the damaged left ventricle as opposed to direct cell injections into the heart or down the coronary arteries. These studies combined with ongoing studies in immune-competent Yucatan mini swine treated with the same xenograft led to the preliminary design of a proposed Phase I clinical trial that will be presented to the Federal Drug Administration. For the proposed Phase I clinical, this TE patch will be implanted onto the epicardial surface of non-immunosuppressed patients undergoing elective Coronary Artery Bypass Grafting with Ejection Fractions ≥ 20% and ≤ 45%. The primary endpoints will be adverse events/severe adverse events associated with placing the TE patch on the heart. While Phase I trials are primarily safety trials, this proposed trial is designed to obtain some potential efficacy endpoints to help with the design of future Phase II/III clinical trials. These endpoints include changes in LV remodeling that were seen in the pre-clinical animal models as well as including endpoints that focus on patient well-being.

show abstract

Section: Outline Of Study Of Tissue Engineered Patch In Yucatan Mini ...mentioning

confidence: 99%

Section: Cardiac Magnetic Resonance (Cmr) Imagingmentioning

confidence: 99%

Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial

Goldman¹,

Traverse²,

Zile³

et al. 2022

Vessel Plus

Self Cite

View full text Add to dashboard Cite

show abstract

“…Incomplete revascularization has been associated with decreased long-term survival for both types of revascularization (either CABG or PCI). 19,20 It would not be an absurd idea to believe that the high rates of completeness of revascularization achieved by the robotic off-pump HCR (by combining grafts and stents) translated into no difference in long-term outcomes when compared with conventional OPCAB via sternotomy in the propensity matched-analysis, which would render this approach more acceptable in terms of clinical outcomes. A question that also rises in this scenario is the following: "are drug-eluting stents as good as SVGs for non-LAD vessels"?…”

Section: Operative Mortality and Long-term Outcomesmentioning

confidence: 99%

Robotic hybrid coronary revascularization versus conventional off‐pump coronary bypass surgery in women with two‐vessel disease

Torregrossa

Sá

Eynde

et al. 2021

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Background: Hybrid coronary revascularization (HCR) treats coronary artery disease (CAD) by combining a minimally invasive surgical approach with the left internal mammary artery (LIMA) to the left anterior descending (LAD) artery and percutaneous coronary intervention (PCI) for non-LAD vessels. This study aimed to compare immediate and long-term outcomes between robotic HCR and off-pump coronary artery bypass (OPCAB) via sternotomy in women with two-vessel CAD. Methods and Results:We compared all robotic HCR (LIMA-to-LAD plus stent; n = 55) and OPCAB (LIMA-to-LAD plus saphenous vein graft; n = 54) performed at a single institution between May 2005 and January 2021. To adjust for the selection bias of receiving either HCR or OPCAB, we performed a propensity score analysis of 31 matched pairs. In the immediate postoperative period, no statistically significant difference was observed for operative mortality and HCR was associated with lower rates of blood transfusion (25.8% vs. 54.8%; p = .038), and shorter hospital length of stay (4.0 vs. 6.0 days; p = .009). After a mean follow-up of 7.0 ± 4.9 years, we observed no statistically significant differences between the groups for overall survival (hazard ratio [HR]: 0.48,

show abstract

Rate of Incomplete Revascularization Following Coronary Artery Bypass Grafting at a Single Institution Between 2007 and 2017

Cited by 2 publications

References 15 publications

Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial

Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial

Robotic hybrid coronary revascularization versus conventional off‐pump coronary bypass surgery in women with two‐vessel disease

Contact Info

Product

Resources

About